Worth reading
45Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
15.1
％Wording
Avoiding a definitive answer
How definitive the wording is.Results for this period
First quarter2025年4月1日〜2025年6月30日Non-consolidated (standalone)Japanese GAAPNet Sales2,168¥ millionYear on year +15.1%Progress 21.7%
Operating profit-143¥ million
Ordinary income-117¥ million
Net income attributable to owners of the parent-108¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share△3.12円
Financial position at period-end
Total assets14,723¥ million
of which net assets 11,420 ¥ millionEquity ratio 77.6%vs. prior year-end +0.2pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenuePharmaceuticals ¥1,100,714 thousand (YoY +39.3%), Healthcare Business ¥599,678 thousand (YoY -3.7%), Global Business ¥424,224 thousand (YoY -0.7%), Real estate leasing ¥43,935 thousand (YoY -1.5%)
Segment profitPharmaceuticals ¥-211,807 thousand, Healthcare Business ¥-1,878 thousand, Global Business ¥55,788 thousand, Real estate leasing ¥14,590 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥10,000 million (YoY +28.4%)
Operating profit¥200 million
Ordinary income¥250 million
Net income¥200 million (YoY +210.4%)
Annual Dividend Forecast¥3.00 → ¥3.00
Factors Behind Changes in Business Performance
医薬事業では「マキュエイド眼注用40mg」の供給再開などにより売上が増加した一方、ヘルスケア事業ではインバウンド需要の変化により「強力わかもと」の売上が減少しました。販売費及び一般管理費は、新製品発売に伴う広告宣伝の強化、専門人財の確保、ベースアップによる人件費増加等により増加しました。
Disclosure regarding the going concern assumption
Not applicable
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Depreciation and amortization¥109,260 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo (no target participants specified)
Issued Shares at Period-End34,838,325 shares
Treasury Shares at Period-End132,057株
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 2025年4月1日〜2025年6月30日 |
| Net Sales | ¥2,168 million (YoY +15.1%) |
| Operating profit | ¥-143 million |
| Ordinary income | ¥-117 million |
| Profit attributable to owners of the parent | ¥-108 million |
| Net income per share | △3.12円 |
| Equity ratio | End of the current fiscal period 77.6% / End of previous period 77.4% |
| Total assets | ¥14,723 million |
| Net assets | ¥11,420 million |
| Full-year earnings forecast | Net Sales ¥10,000 million (YoY +28.4%) / Operating profit ¥200 million / Ordinary income ¥250 million / Net income ¥200 million (YoY +210.4%) |
| Annual Dividend Forecast | ¥3.00 → ¥3.00 |
| Segment revenue | Pharmaceuticals ¥1,100,714 thousand (YoY +39.3%), Healthcare Business ¥599,678 thousand (YoY -3.7%), Global Business ¥424,224 thousand (YoY -0.7%), Real estate leasing ¥43,935 thousand (YoY -1.5%) |
| Segment profit | Pharmaceuticals ¥-211,807 thousand, Healthcare Business ¥-1,878 thousand, Global Business ¥55,788 thousand, Real estate leasing ¥14,590 thousand |
| Depreciation and amortization | ¥109,260 thousand |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No (no target participants specified) |
| Issued Shares at Period-End | 34,838,325 shares |
| Treasury Shares at Period-End | 132,057株 |
| Factors Behind Changes in Business Performance | 医薬事業では「マキュエイド眼注用40mg」の供給再開などにより売上が増加した一方、ヘルスケア事業ではインバウンド需要の変化により「強力わかもと」の売上が減少しました。販売費及び一般管理費は、新製品発売に伴う広告宣伝の強化、専門人財の確保、ベースアップによる人件費増加等により増加しました。 |
Items this document does not state (14)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Changes in the scope of consolidationMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.医薬事業では「マキュエイド眼注用40mg」の供給再開などで売上が増加しました。一方、インバウンド需要の変化で「強力わかもと」の売上が減少し、新製品発売に伴う広告宣伝費、専門人財の確保やベースアップによる人件費も増加しました。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.